Table 2.
Polymorphisms in lipid metabolizing genes and risk of CKD
| Polymorphism | Genotype | CKD (+) | CKD (-) | Per allele | P |
|---|---|---|---|---|---|
| (n = 564) | (n = 2,704) | aOR (95% CI)* | |||
| APOA1 Ala61Thr (G219A) | G/G | 506 (89.7%) | 2,423 (89.6%) | ||
| (rs12718465) | A/G | 56 (9.9%) | 268 (9.9%) | 0.98 (0.74-1.31) | 0.901 |
| A/A | 2 (0.4%) | 13 (0.5%) | |||
| APOA5 G553T (Cys185Gly) | G/G | 483 (85.6%) | 2,375 (87.8%) | ||
| (rs2075291) | G/T | 79 (14.0%) | 309 (11.4%) | 1.12 (0.87-1.43) | 0.378 |
| T/T | 2 (0.4%) | 20 (0.7%) | |||
| APOA5 T-1131C | T/T | 221 (39.2%) | 1,197 (44.3%) | ||
| (rs662799) | C/T | 258 (45.7%) | 1,183 (43.8%) | 1.22 (1.06-1.39) | 0.004 |
| C/C | 85 (15.1%) | 324 (12.0%) | |||
| APOA5 C/A | C/C | 210 (37.2%) | 1,028 (38.0%) | ||
| (rs6589567) | C/A | 264 (46.8%) | 1,241 (45.9%) | 1.03 (0.90-1.17) | 0.684 |
| A/A | 90 (16.0%) | 435 (16.1%) | |||
| APOA5 T1259C | T/T | 282 (50.0%) | 1,437 (53.1%) | ||
| (rs2266788) | T/C | 224 (39.7%) | 1,059 (39.2%) | 1.19 (1.03-1.37) | 0.019 |
| C/C | 58 (10.3%) | 208 (7.7%) | |||
| APOB A/G | A/A | 308 (54.6%) | 1,421 (52.6%) | ||
| (rs673548) | A/G | 210 (37.2%) | 1,056 (39.1%) | 0.95 (0.82-1.10) | 0.490 |
| G/G | 46 (8.2%) | 227 (8.4%) | |||
| APOE Arg158Cys (C609T) | C/C | 523 (92.7%) | 2,472 (91.4%) | ||
| (rs7412) | C/T | 40 (7.1%) | 226 (8.4%) | 0.82 (0.58-1.15) | 0.255 |
| T/T | 1 (0.2%) | 6 (0.2%) | |||
| APOE Cys112Arg (T471C) | T/T | 469 (83.2%) | 2,200 (81.4%) | ||
| (rs429358) | T/C | 88 (15.6%) | 466 (17.2%) | 0.91 (0.73-1.13) | 0.388 |
| C/C | 7 (1.2%) | 38 (1.4%) | |||
| APOE T-219G | T/T | 290 (51.4%) | 1,317 (48.7%) | ||
| (rs405509) | T/G | 228 (40.4%) | 1,090 (40.3%) | 0.90 (0.78-1.03) | 0.124 |
| G/G | 46 (8.2%) | 297 (11.0%) | |||
| APOE cluster A/G | A/A | 452 (80.1%) | 2,155 (79.7%) | ||
| (rs4420638) | A/G | 104 (18.4%) | 509 (18.8%) | 0.97 (0.79-1.20) | 0.798 |
| G/G | 8 (1.4%) | 40 (1.5%) | |||
| TOMM40 A/G | A/A | 118 (20.9%) | 825 (30.5%) | ||
| (rs157580) | A/G | 299 (53.0%) | 1,257 (46.5%) | 1.27 (1.12-1.45) | <0.001 |
| G/G | 147 (26.1%) | 622 (23.0%) | |||
| HMGCR G/A | G/G | 163 (28.9%) | 736 (27.2%) | ||
| (rs3846662) | G/A | 278 (49.3%) | 1,326 (49.0%) | 0.91 (0.80-1.04) | 0.162 |
| A/A | 123 (21.8%) | 642 (23.7%) | |||
| LPL G/A | G/G | 366 (64.9%) | 1,797 (66.5%) | ||
| (rs331) | G/A | 177 (31.4%) | 816 (30.2%) | 1.04 (0.88-1.22) | 0.681 |
| A/A | 21 (3.7%) | 91 (3.4%) | |||
| LPL G1791C (Ser474Stop) | G/G | 423 (75.0%) | 2,083 (77.0%) | ||
| (rs328) | G/C | 131 (23.2%) | 579 (21.4%) | 1.07 (0.89-1.30) | 0.466 |
| C/C | 10 (1.8%) | 42 (1.6%) | |||
| NR1H3 G/A | G/G | 301 (53.4%) | 1,512 (55.9%) | ||
| (rs7120118) | G/A | 224 (39.7%) | 1,027 (38.0%) | 1.12 (0.97-1.31) | 0.125 |
| A/A | 39 (6.9%) | 165 (6.1%) | |||
| NR1H3 A/G | A/A | 299 (53.0%) | 1,524 (56.4%) | ||
| (rs2167079) | A/G | 227 (40.2%) | 1,017 (37.6%) | 1.14 (0.99-1.33) | 0.078 |
| G/G | 38 (6.7%) | 163 (6.0%) | |||
| MTNR1B A/G | A/A | 250 (44.3%) | 1,245 (46.0%) | ||
| (rs1447352) | A/G | 247 (43.8%) | 1,176 (43.5%) | 1.06 (0.92-1.22) | 0.392 |
| G/G | 67 (11.9%) | 283 (10.5%) | |||
| FADS2 C/T | C/C | 227 (40.2%) | 979 (36.2%) | ||
| (rs174570) | C/T | 250 (44.3%) | 1,266 (46.8%) | 0.91 (0.80-1.04) | 0.167 |
| T/T | 87 (15.4%) | 459 (17.0%) | |||
| KCNJ11 A1577G (Ile337Val) | A/A | 240 (42.6%) | 1,068 (39.5%) | ||
| (rs5215) | A/G | 241 (42.7%) | 1,274 (47.1%) | 0.95 (0.83-1.09) | 0.485 |
| G/G | 83 (14.7%) | 362 (13.4%) | |||
| TMEM57 A/G | A/A | 256 (45.4%) | 1,186 (43.9%) | ||
| (rs10903129) | A/G | 254 (45.0%) | 1,234 (45.6%) | 0.90 (0.78-1.04) | 0.168 |
| G/G | 54 (9.6%) | 284 (10.5%) | |||
| DOCK7 A/C | A/A | 347 (61.5%) | 1,542 (57.0%) | ||
| (rs1167998) | A/C | 188 (33.3%) | 996 (36.8%) | 0.86 (0.74-1.01) | 0.061 |
| C/C | 29 (5.1%) | 166 (6.1%) | |||
| CELSR2 C/T | C/C | 516 (91.5%) | 2,413 (89.2%) | ||
| (rs4970834) | C/T | 46 (8.2%) | 280 (10.4%) | 0.79 (0.58-1.07) | 0.133 |
| T/T | 2 (0.4%) | 11 (0.4%) | |||
| LIPC Val95Met (G340A) | G/G | 342 (60.6%) | 1,616 (59.8%) | ||
| (rs6078) | G/A | 193 (34.2%) | 945 (34.9%) | 0.96 (0.82-1.13) | 0.643 |
| A/A | 29 (5.1%) | 143 (5.3%) | |||
| LIPC T-514C | T/T | 132 (23.4%) | 731 (27.0%) | ||
| (rs1800588) | T/C | 290 (51.4%) | 1,353 (50.0%) | 1.10 (0.97-1.26) | 0.143 |
| C/C | 142 (25.2%) | 620 (22.9%) | |||
| CETP TaqIB (G > A) | G/G | 234 (41.5%) | 934 (34.5%) | ||
| (rs708272) | G/A | 251 (44.5%) | 1,315 (48.6%) | 0.81 (0.71-0.92) | 0.002 |
| A/A | 79 (14.0%) | 455 (16.8%) | |||
| CETP G/T | G/G | 372 (66.0%) | 1,692 (62.6%) | ||
| (rs3764261) | G/T | 170 (30.1%) | 872 (32.2%) | 0.86 (0.73-1.01) | 0.068 |
| T/T | 22 (3.9%) | 140 (5.2%) | |||
| CETP Ile405Val (G > A) | G/G | 147 (26.1%) | 753 (27.8%) | ||
| (rs5882) | G/A | 277 (49.1%) | 1,312 (48.5%) | 1.06 (0.93-1.20) | 0.403 |
| A/A | 140 (24.8%) | 639 (23.6%) | |||
| CETP A-629C | A/A | 162 (28.7%) | 825 (30.5%) | ||
| (rs1800775) | A/C | 279 (49.5%) | 1,366 (50.5%) | 1.10 (0.96-1.25) | 0.174 |
| C/C | 123 (21.8%) | 513 (19.0%) |
*aOR: adjusted odds ratio (adjusted for age and sex); 95% CI: 95% confidence interval; CKD: chronic kidney disease.